{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:24Z","timestamp":1761100524041},"reference-count":122,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1997,6,1]],"date-time":"1997-06-01T00:00:00Z","timestamp":865123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":8244,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1997,6]]},"DOI":"10.1023\/a:1008248315859","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T13:47:34Z","timestamp":1040564854000},"page":"515-524","source":"Crossref","is-referenced-by-count":15,"title":["Central nervous system relapse of lymphoid malignancies in adults: The role of high-dose chemotherapy"],"prefix":"10.1016","volume":"8","author":[{"given":"K.","family":"van Besien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008248315859_bb0005","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.1991.9.9.1580","article-title":"Primary CNS lymphoma treated with osmotic blood\u2013brain barrier disruption: Prolonged survival and preservation of cognitive function","volume":"9","author":"Neuwelt","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0010","first-page":"155","article-title":"Primary central nervous system lymphoma Recent Results","volume":"135","author":"DeAngelis","year":"1994","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0015","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood.V86.8.2873.2873","article-title":"Treatment of primary central nervous system lymphoma: Still more questions than answers","volume":"86","author":"Fine","year":"1995","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0020","first-page":"664","article-title":"Small noncleaved cell lymphoma and leukemia in adults","volume":"85","author":"Soussain","year":"1995","journal-title":"A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood"},{"key":"10.1023\/A:1008248315859_bb0025","first-page":"1973","article-title":"J Clin Oncol","volume":"9","author":"Haddy","year":"1991","journal-title":"involvement in small noncleaved-cell lymphoma' Is CNS disease per se a poor prognostic sign?"},{"key":"10.1023\/A:1008248315859_bb0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/1097-0142(19900801)66:3<447::AID-CNCR2820660308>3.0.CO;2-5","article-title":"Delayed central nervous system (CNS) radiation in childhood CNS acute lymphoblastic leukemia. Results of a pilot trial","volume":"66","author":"Mandell","year":"1990","journal-title":"Cancer"},{"key":"10.1023\/A:1008248315859_bb0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.1995.13.2.310","article-title":"CNS leukemia: Problem of diagnosis, treatment and outcome","volume":"13","author":"Steinherz","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V84.2.355.355","article-title":"Prevention and treatment of meningeal leukemia in children","volume":"84","author":"Pinkel","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0045","first-page":"515","article-title":"Isolated extramedullary relapse in children with acute lymphoblastic leukemia: A comparison between treatment results of chemotherapy and bone marrow transplantation","volume":"15","author":"Borgmann","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0050","first-page":"1249","article-title":"Central nervous system relapse in malignant lymphomas","volume":"54","author":"Litam","year":"1979","journal-title":"Risk factors and implications for prophylaxis. Blood"},{"key":"10.1023\/A:1008248315859_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0002-9343(88)90262-8","article-title":"Central nervous system metastases from non-Hodgkin's lymphoma: Treatment and prophylaxis","volume":"84","author":"Recht","year":"1988","journal-title":"Am J Med"},{"key":"10.1023\/A:1008248315859_bb0060","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00000421-199112000-00004","article-title":"Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma","volume":"14","author":"Bashir","year":"1991","journal-title":"Am J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0065","first-page":"390","article-title":"Involvement of the central nervous system by non-Hodgkin's lymphoma","volume":"43","author":"Herman","year":"1979","journal-title":"The Southwest Oncology Group Experience. Cancer"},{"key":"10.1023\/A:1008248315859_bb0070","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/1097-0142(19800201)45:3<545::AID-CNCR2820450322>3.0.CO;2-6","article-title":"CNS involvement in the non-Hodgkin's lymphomas","volume":"45","author":"Levitt","year":"1980","journal-title":"Cancer"},{"key":"10.1023\/A:1008248315859_bb0075","first-page":"5","article-title":"Bone marrow transplantation activity in Europe 1992: Report from the European Group for Bone Marrow Transplantation (EBMT)","volume":"13","author":"Gratwohl","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0080","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","article-title":"The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia","volume":"86","author":"Cortes","year":"1995","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0085","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.1994.12.11.2415","article-title":"Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: Those transplanted with active CNS disease have a poor outcome \u2014 a report by the European Bone Marrow Transplant Lymphoma Registry","volume":"12","author":"Williams","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0090","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.1996.14.11.3036","article-title":"High-dose thiotepa, busulfan and cyclophosphamide for patients with hematologic malignancies and CNS involvement","volume":"14","author":"van Besien","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood.V67.1.195.195","article-title":"The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia","volume":"67","author":"Thompson","year":"1986","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0100","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/1097-0142(19891101)64:9<1796::AID-CNCR2820640907>3.0.CO;2-7","article-title":"Central nervous system relapses after bone marrow transplantation for acute lymphoblastic leukemia in remission","volume":"64","author":"Ganem","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1008248315859_bb0105","first-page":"384a","article-title":"Allogeneic bone marrow transplantation is the best treatment for early meningeal relapses in non-previously irradiated children with acute lymphoblastic leukemia","volume":"86","author":"Baruchel","year":"1995","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.1988.6.7.1118","article-title":"High dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy for diffuse non-Hodgkin's lymphoma","volume":"6","author":"Philip","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0115","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/0360-3016(83)90364-4","article-title":"Techniques of magna-field irradiation","volume":"9","author":"Shank","year":"1983","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1023\/A:1008248315859_bb0120","series-title":"Bone Marrow Transplantation","first-page":"96","article-title":"Radiotherapeutic principles of bone marrow transplantation","author":"Shank","year":"1994"},{"issue":"10","key":"10.1023\/A:1008248315859_bb0125","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.1991.9.8.1348","article-title":"A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation","volume":"9","author":"Mulhern","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0130","first-page":"499","article-title":"Post-irradiation somnolence syndrome in an adult patient following allogeneic bone marrow transplantation","volume":"9","author":"Goldberg","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0135","first-page":"269","article-title":"Cognitive dysfunction in adult survivors of of allogeneic marrow transplantation: Relationship to dose of total body irradiation","volume":"6","author":"Andrykowski","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0140","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood.V84.6.2036.2036","article-title":"Marrow transplantation for chronic myeloid leukemia' A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0145","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V85.8.2263.bloodjournal8582263","article-title":"Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: A randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the French Society of Bone Marrow Graft (SFGM)","volume":"85","author":"Devergie","year":"1995","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0150","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/10428199509056853","article-title":"A phase I\u2013II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma","volume":"17","author":"Przepiorka","year":"1995","journal-title":"Leuk Lymph"},{"key":"10.1023\/A:1008248315859_bb0155","first-page":"113","article-title":"Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy","volume":"4","author":"Hassan","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF03190094","article-title":"Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain","volume":"13","author":"Hassan","year":"1988","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1023\/A:1008248315859_bb0165","first-page":"577","article-title":"Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies","volume":"13","author":"Bandini","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0170","first-page":"363","article-title":"High dose busulfan and seizures","volume":"7","author":"De la Camara","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0175","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1200\/JCO.1991.9.7.1224","article-title":"Regimen-related toxicity of a busulfan\u2013cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation","volume":"9","author":"Nevill","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0180","first-page":"189","article-title":"CNS toxicity and high-dose busulphan in three patients undergoing bone marrow transplantation","volume":"77","author":"Vasta","year":"1992","journal-title":"Haematol"},{"key":"10.1023\/A:1008248315859_bb0185","first-page":"896","article-title":"Metabolism of radioactive cyclophopshamide","volume":"20","author":"Graul","year":"1967","journal-title":"Animal tests and clinical studies. Cancer"},{"key":"10.1023\/A:1008248315859_bb0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1227\/00006123-198402000-00006","article-title":"Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: Observations on problems of drug delivery","volume":"14","author":"Neuwelt","year":"1984","journal-title":"Neurosurg"},{"key":"10.1023\/A:1008248315859_bb0195","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/bjc.1980.17","article-title":"Distribution and pharmacokinetics of cyclophosphamide in the rat","volume":"41","author":"Talha","year":"1980","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008248315859_bb0200","first-page":"335","volume":"18","author":"Friedman","year":"1986","journal-title":"Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma Neurosurgery"},{"key":"10.1023\/A:1008248315859_bb0205","first-page":"749","volume":"55","author":"Allen","year":"1981","journal-title":"High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children J Neurosurg"},{"key":"10.1023\/A:1008248315859_bb0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00043426-198921000-00017","volume":"11","author":"Balis","year":"1989","journal-title":"Central nervous pharmacology of antileukemic drugs Am J Pediatr Hematol Oncol"},{"key":"10.1023\/A:1008248315859_bb0215","first-page":"107","article-title":"Pharmacologic approaches to the treatment of meningeal malignancy","volume":"5","author":"Blaney","year":"1991","journal-title":"Oncology"},{"key":"10.1023\/A:1008248315859_bb0220","first-page":"1154","article-title":"Experimental evaluation of potential anticancer agents","volume":"21","author":"Skipper","year":"1961","journal-title":"VI. Anatomical distribution of leukemic cells and failure of chemotherapy Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0225","first-page":"1355","article-title":"Pathology of the spread of L1210 leukemia in the central nervous system of mice and effect of treatment with Cytoxan","volume":"28","author":"Thomas","year":"1962","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008248315859_bb0230","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ijc.2910180521","article-title":"An experimental model for meningeal leukemia in rats (L5222) Effect of treatment with BCNU and cyclophosphamide","volume":"18","author":"Fiebig","year":"1976","journal-title":"Int J Cancer"},{"key":"10.1023\/A:1008248315859_bb0235","first-page":"465","article-title":"High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma","volume":"8","author":"Avet-Loiseau","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0240","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: Evidence for dose-dependent plasma clearance of thiotepa","volume":"49","author":"Heideman","year":"1989","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0245","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan A review","volume":"13","author":"Samuels","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0250","first-page":"90","article-title":"High dose thiotepa with autologous bone marrow transplantation and localized radiotherapy for patients with astrocytoma grade III\u2013IV (glioma)","volume":"8","author":"Ascensao","year":"1989","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 3","key":"10.1023\/A:1008248315859_bb0255","first-page":"2","article-title":"High-dose N,N',N\" -triethy-lenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies","volume":"17","author":"Wolff","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008248315859_bb0260","first-page":"549","article-title":"Intensive chemotherapy with the BEAC regimen and autologous bone marrow transplantation in patients with refractory or recurrent intermediate grade and immunoblastic lymphoma; toxicity, long-term follow-up and identification of prognostic factors","volume":"15","author":"van Besien","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0265","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.1993.11.12.2351","article-title":"One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome","volume":"11","author":"Rapoport","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0270","first-page":"1137","article-title":"The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease","volume":"81","author":"Chopra","year":"1993","journal-title":"A single-center eight-year study of 155 patients. Blood"},{"key":"10.1023\/A:1008248315859_bb0275","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0280","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1200\/JCO.1993.11.6.1085","article-title":"Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide","volume":"11","author":"Wheeler","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0285","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7326\/0003-4819-104-2-163","article-title":"High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease","volume":"104","author":"Jagannath","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1023\/A:1008248315859_bb0290","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/cpt196784566","article-title":"The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-l-nitro-sourea (BCNU) in man and animals","volume":"8","author":"DeVita","year":"1967","journal-title":"Clin Pharmacol Ther"},{"key":"10.1023\/A:1008248315859_bb0295","first-page":"220","article-title":"The chemotherapy of high-grade astrocytomas","volume":"21","author":"Lesser","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008248315859_bb0300","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1200\/JCO.1986.4.5.639","article-title":"Intensive l,3-bis(2-chloroethyl) -l-nitrosourea (BCNU) monochemotherapy and autologous marrow tranplantation for malignant glioma","volume":"4","author":"Phillips","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0305","first-page":"610","volume":"1","author":"Takvorian","year":"1983","journal-title":"Autologous bone-marrow transplantation: Host-effects of high dose BCNU J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0310","first-page":"1792","article-title":"Intensive l,3-bis(2-chloroethyl) -l-nitorosurea(BCNU),NSC#4366650 and cryopre-served autologous marrow transplantation for refractory cancer","volume":"52","author":"Phillips","year":"1983","journal-title":"A phase I\u2013II study. Cancer"},{"key":"10.1023\/A:1008248315859_bb0315","first-page":"183","article-title":"High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system","volume":"71","author":"Wolff","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1023\/A:1008248315859_bb0320","first-page":"34","article-title":"The place of hydroxyurea in the treatment of primary brain tumors","volume":"3","author":"Levin","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008248315859_bb0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/oxfordjournals.annonc.a057826","article-title":"Concentrations of VP 16 and VM 26 in human brain tumors","volume":"2","author":"Zucchetti","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008248315859_bb0330","first-page":"241","article-title":"Intravenous etoposide therapy achieves potentially cytotoxic concentration in cerebrospinal fluid of children with acute lymphoblastic leukemia","volume":"35","author":"Relling","year":"1994","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0335","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.1984.2.5.432","article-title":"Etoposide in malignant brain tumors: A phase II study","volume":"2","author":"Tirelli","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0340","first-page":"759","article-title":"Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation","volume":"71","author":"Giannone","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1023\/A:1008248315859_bb0345","first-page":"92","article-title":"Phase II trial of high dose etoposide (E) and autologous bone marrow transplantation (ABMT) for treatment of progressive glioma","volume":"8","author":"Long","year":"1989","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0350","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1200\/JCO.1995.13.2.333","article-title":"An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia","volume":"13","author":"Ribeiro","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1983.1.6.359","article-title":"Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer","volume":"1","author":"Lazarus","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0360","series-title":"Lancet","first-page":"966","article-title":"Acceleration of bone marrow recovery by pretreatment with cyclophosphamide in patients receiving high dose melphalan","author":"Hedley","year":"1978"},{"key":"10.1023\/A:1008248315859_bb0365","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF00256174","article-title":"Pharmacokinetics of high dose melphalan in children and adults","volume":"16","author":"Gouyette","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008248315859_bb0370","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00293997","article-title":"Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis","volume":"16","author":"Ardiet","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008248315859_bb0375","first-page":"397","article-title":"Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan","volume":"40","author":"Brown","year":"1990","journal-title":"Neurology"},{"key":"10.1023\/A:1008248315859_bb0380","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00000421-198802000-00011","article-title":"A phase II trial of oral melphalan in recurrent primary brain tumors","volume":"11","author":"Chamberlain","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0385","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1200\/JCO.1988.6.11.1768","article-title":"The systemic administration of intravenous melphalan","volume":"6","author":"Sarosy","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0390","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/1097-0142(19850101)55:1<44::AID-CNCR2820550107>3.0.CO;2-B","article-title":"Syndrome of inappropriate antidiuretic hormone secretion: a complication of high dose intravenous melphalan","volume":"55","author":"Greenbaum-Lefkoe","year":"1985","journal-title":"Cancer"},{"key":"10.1023\/A:1008248315859_bb0395","first-page":"6101","article-title":"Pharmacokinetics of intraventricular and intravenous N,N',N\"-triethylenethiophos-phoramide (thiotepa) in Rhesus monkeys and humans","volume":"46","author":"Strong","year":"1986","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0400","first-page":"625","article-title":"Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: A Childrens Cancer Study Group report","volume":"50","author":"Reid","year":"1990","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0405","series-title":"Bone Marrow Transplantation","first-page":"231","article-title":"Graft-versus-tumor responses: Adoptive cellular therapy in bone marrow transplantation","author":"Fefer","year":"1994"},{"key":"10.1023\/A:1008248315859_bb0410","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1008248315859_bb0415","first-page":"180","article-title":"Lack of a graft-versus-leukemia effect in an immunologically privileged site","volume":"14","author":"Goldberg","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0420","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.35.3.300","article-title":"Neurologic complications of bone marrow transplantation","volume":"35","author":"Patchell","year":"1985","journal-title":"Neurology"},{"key":"10.1023\/A:1008248315859_bb0425","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0167-5699(94)90247-X","article-title":"Nervous tissue as an immune compartment: The dialect of the immune response in the CNS","volume":"15","author":"Fabry","year":"1994","journal-title":"Immunol Today"},{"key":"10.1023\/A:1008248315859_bb0430","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","article-title":"Treatment of childhood acute lymphoblastic leukemia Results of Dana-Farber Cancer Institute\/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01","volume":"12","author":"Schorin","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0435","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF00230498","article-title":"Subacute panencephalitis associated with chronic graft-versus-host disease","volume":"85","author":"Iwasaki","year":"1993","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1023\/A:1008248315859_bb0440","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00005072-199309000-00004","article-title":"Male donor-derived cells in the brains of female sex-mismatched bone marrow transplant recipients: A Y-chromosome specific in situ hybridization study","volume":"52","author":"Unger","year":"1993","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1023\/A:1008248315859_bb0445","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.4049\/jimmunol.138.12.4293","article-title":"Granulocyte-macrophage colony stimulating factor produced by cloned L3T4a+ class II-restncted T cells induce HT-2 cells to proliferate","volume":"138","author":"Woods","year":"1987","journal-title":"J Immunol"},{"key":"10.1023\/A:1008248315859_bb0450","series-title":"Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate grade lymphoma","author":"van Besien","year":"1996"},{"key":"10.1023\/A:1008248315859_bb0455","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.1983.1.9.542","article-title":"Cranial nerve involvement in children with leukemia and lymphoma","volume":"1","author":"Paryani","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0460","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0360-3016(90)90555-X","article-title":"Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia","volume":"19","author":"Gray","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1023\/A:1008248315859_bb0465","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/1097-0142(197507)36:1<225::AID-CNCR2820360125>3.0.CO;2-A","article-title":"Involvement of the central nervous system in non-Hodgkin's lymphoma","volume":"36","author":"Law","year":"1975","journal-title":"Cancer"},{"key":"10.1023\/A:1008248315859_bb0470","first-page":"534","volume":"169","author":"Gregoire","year":"1993","journal-title":"Alteration of the blood-brain barrier after irradiation: Implication in boron neutron capture therapy Strahlenther Onkol"},{"key":"10.1023\/A:1008248315859_bb0475","series-title":"Implications of the Blood\u2013Brain Barrier and its Manipulations","first-page":"373","article-title":"Chemoradiotherapy interactions and the blood\u2013brain barrier","author":"Mahler","year":"1989"},{"key":"10.1023\/A:1008248315859_bb0480","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0360-3016(90)90376-U","article-title":"Effects of ionizing radiation on the blood brain barrier permeability to pharmacologically active substances","volume":"19","author":"Trnovec","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1023\/A:1008248315859_bb0485","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bmt.1700692","article-title":"Allogeneic blood stem cell transplantation in advanced hematologic malignancies","volume":"19","author":"Przepiorka","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0490","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/oxfordjournals.annonc.a058324","article-title":"A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'","volume":"3","author":"Rodriguez","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008248315859_bb0495","first-page":"1289","article-title":"Modifed chemotherapy with carmustine, cytarabine, cyclophosphamide and 6-thioguanine (BACT) and autologous bone marrow transplantation in 24 poor risk patients with acute lymphoblastic leukemia","volume":"76","author":"Pico","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008248315859_bb0500","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1200\/JCO.1990.8.5.809","article-title":"Allogeneic bone marrow transplantation in adults with Burkitt's lymphoma or acute lymphoblastic leukemia in first complete remission","volume":"8","author":"Troussard","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0505","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2141.1989.tb00224.x","article-title":"Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission","volume":"73","author":"Milpied","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1023\/A:1008248315859_bb0510","first-page":"37","article-title":"ABMT for early isolated extramedullary relapse of childhood ALL","volume":"12","author":"Rossetti","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0515","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.1994.tb03253.x","article-title":"Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: Risk factors and clinical outcome","volume":"86","author":"Weisdorf","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1023\/A:1008248315859_bb0520","first-page":"353","article-title":"Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma","volume":"15","author":"Bureo","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1023\/A:1008248315859_bb0525","series-title":"Autologous Bone Marrow Transplantation. Proceedings of the 3rd international symposium","article-title":"High dose chemotherapy with autologous marrow transplantation for gliomas of the central nervous system","author":"Wolff","year":"1987"},{"key":"10.1023\/A:1008248315859_bb0530","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00000421-198804000-00013","article-title":"Platinum concentrations in human autopsy tumor samples","volume":"11","author":"Stewart","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0535","first-page":"1661","article-title":"Platinum concentration in human glioblastoma multiforme following the use of cisplatin","volume":"66","author":"Bonnern","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1023\/A:1008248315859_bb0540","first-page":"2474","article-title":"Human central nervous system distribution of cis-diamminedichloroplatinum and its use as a radiosensitizer in malignant brain tumors","volume":"42","author":"Stewart","year":"1982","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0545","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00182960","article-title":"Phase II study of cisplatin in recurrent astrocytomas in adults: A Southwest oncology group study","volume":"1","author":"Stewart","year":"1983","journal-title":"J Neurooncol"},{"key":"10.1023\/A:1008248315859_bb0550","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/cdd.1987.4.47","article-title":"Treatment of astrocytoma with a 5-day cisplatin infusion","volume":"4","author":"Grunberg","year":"1987","journal-title":"Cancer Drug Delivery"},{"key":"10.1023\/A:1008248315859_bb0555","first-page":"281","article-title":"Treatment of recurrent glioma with carboplatin (CBDCA)","volume":"6","author":"Walker","year":"1987","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0560","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3171\/jns.1990.72.5.0721","article-title":"The disposition of TCNU (tauromustine) in human malignant glioma: Pharmacokinetic studies and clinical implications","volume":"72","author":"Whittle","year":"1990","journal-title":"J Neurosurg"},{"key":"10.1023\/A:1008248315859_bb0565","first-page":"3120","article-title":"Pharmacokinetics of positronlabeled l,3-bis(2chlor-ethyl)mtrosourea in human brain tumors using positron emission tomography","volume":"44","author":"Diksic","year":"1984","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0570","first-page":"133","article-title":"Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors","volume":"2","author":"Stewart","year":"1984","journal-title":"J Neurooncol"},{"key":"10.1023\/A:1008248315859_bb0575","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1200\/JCO.1984.2.5.365","article-title":"Successful treatment of meningeal leukemia using systemic high dose cytosine arabinoside","volume":"2","author":"Frick","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0580","first-page":"57","article-title":"Hydroxyurea in biologic fluids: Dose-concentration relationship","volume":"48","author":"Beckloff","year":"1963","journal-title":"Cancer Chemother Rep"},{"key":"10.1023\/A:1008248315859_bb0585","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.1995.13.5.1089","article-title":"Phase I\/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma","volume":"13","author":"Vaughan","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0590","first-page":"1869","article-title":"Phase I and clinical pharmacologic study of mercaptopurine administered as a prolonged intravenous infusion","volume":"45","author":"Zimm","year":"1985","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008248315859_bb0595","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.1994.12.7.1383","article-title":"Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study","volume":"12","author":"Camitta","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0600","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1985.3.4.485","article-title":"Remission induction of meningeal leukemia with high-dose intravenous methotrexate","volume":"3","author":"Balis","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0605","first-page":"82","article-title":"High dose methotrexate (HDMTX) with citrovorum factor (CF) in astrocytomas","volume":"7","author":"Djerassi","year":"1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008248315859_bb0610","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/1097-0142(19850615)55:12<2741::AID-CNCR2820551202>3.0.CO;2-2","article-title":"Response of astrocytoma to high-dose methotrexate with citrovorum factor","volume":"55","author":"Djerassi","year":"1985","journal-title":"Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341948277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341948277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/8\/6\/515\/19480933\/8-6-515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:41:40Z","timestamp":1682008900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341948277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["S092375341948277X"],"URL":"https:\/\/doi.org\/10.1023\/a:1008248315859","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}